China Resources Double-Crane Pharmaceutical Co Ltd banner
C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 17.85 CNY -0.61% Market Closed
Market Cap: ¥18.5B

EV/GP

2.7
Current
6%
Cheaper
vs 3-y average of 2.9

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
2.7
=
Enterprise Value
¥17.8B
/
Gross Profit
¥6.4B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
2.7
=
Enterprise Value
¥17.8B
/
Gross Profit
¥6.4B

Valuation Scenarios

China Resources Double-Crane Pharmaceutical Co Ltd is trading below its 3-year average

If EV/GP returns to its 3-Year Average (2.9), the stock would be worth ¥18.92 (6% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+398%
Average Upside
147%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 2.7 ¥17.85
0%
3-Year Average 2.9 ¥18.92
+6%
5-Year Average 2.9 ¥18.82
+5%
Industry Average 7.6 ¥49.48
+177%
Country Average 13.6 ¥88.92
+398%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
18.5B CNY 2.7 11.3
US
Eli Lilly and Co
NYSE:LLY
883B USD 16.9 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.3 27.6
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.7 14.8
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.4 17.3

Market Distribution

Lower than 91% of companies in China
Percentile
9th
Based on 6 967 companies
9th percentile
2.7
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
18.5B CNY
Industry
Pharmaceuticals

In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.

Intrinsic Value
27.78 CNY
Undervaluation 36%
Intrinsic Value
Price ¥17.85
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett